Corcept Therapeutics Incorporated
CORT
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 dā¦ read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$73.72
Price+0.90%
$0.66
1Y
Price
Market Cap
$7.754b
Mid
Price/Earnings 3y Avg5y Avg
84.7x
Premium
Premium
Financials Overview
Key metrics over the past few years+14.0%
EBITDA Margin+18.1%
Net Profit Margin+22.6%
Free Cash Flow MarginRevenue
$716.080m
+6.1%
1y CAGR+22.0%
3y CAGR+19.0%
5y CAGREarnings
$132.516m
-5.2%
1y CAGR+10.4%
3y CAGR+5.3%
5y CAGREPS
$1.13
-8.1%
1y CAGR+10.3%
3y CAGR+7.1%
5y CAGRBook Value
$635.793m
$801.722m
Assets$165.929m
Liabilities$6.605m
DebtDebt to Assets
0.8%
0.1x
Debt to EBITDAFree Cash Flow
$180.279m
-8.0%
1y CAGR+17.4%
3y CAGR+6.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company